NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 37 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $175,291 | +10.5% | 211,194 | -6.8% | 0.00% | – |
| Q1 2023 | $158,686 | +4.3% | 226,694 | -24.2% | 0.00% | – |
| Q4 2022 | $152,209 | -30.8% | 299,036 | -12.9% | 0.00% | -100.0% |
| Q3 2022 | $220,000 | -31.7% | 343,136 | +9.8% | 0.00% | 0.0% |
| Q2 2022 | $322,000 | -29.8% | 312,473 | +28.1% | 0.00% | 0.0% |
| Q1 2022 | $459,000 | -38.9% | 243,970 | +56.5% | 0.00% | -50.0% |
| Q4 2021 | $751,000 | -13.6% | 155,895 | +29.7% | 0.00% | 0.0% |
| Q3 2021 | $869,000 | +140.7% | 120,212 | +207.5% | 0.00% | +100.0% |
| Q2 2021 | $361,000 | +97.3% | 39,092 | +162.6% | 0.00% | – |
| Q1 2021 | $183,000 | -92.3% | 14,887 | -91.2% | 0.00% | -100.0% |
| Q4 2020 | $2,379,000 | +35.5% | 168,737 | +15.3% | 0.01% | +16.7% |
| Q3 2020 | $1,756,000 | +17.3% | 146,332 | +62.2% | 0.01% | -14.3% |
| Q2 2020 | $1,497,000 | +240.2% | 90,204 | +133.2% | 0.01% | +75.0% |
| Q1 2020 | $440,000 | +160.4% | 38,677 | +182.4% | 0.00% | +300.0% |
| Q4 2019 | $169,000 | -10.6% | 13,696 | -79.4% | 0.00% | 0.0% |
| Q3 2019 | $189,000 | – | 66,363 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,225,000 | $15,080,000 | 2.22% |
| EcoR1 Capital, LLC | 3,122,704 | $38,440,000 | 1.70% |
| Redmile Group, LLC | 4,117,569 | $50,687,000 | 0.71% |
| HighVista Strategies LLC | 71,235 | $877,000 | 0.65% |
| Boxer Capital, LLC | 1,501,058 | $18,478,000 | 0.63% |
| Baker Brothers Advisors | 3,821,740 | $47,046,000 | 0.20% |
| Sio Capital Management, LLC | 38,312 | $472,000 | 0.10% |
| Highland Private Wealth Management | 46,999 | $579,000 | 0.10% |
| Point72 Asset Management, L.P. | 1,308,600 | $16,109,000 | 0.08% |
| Granahan Investment Management | 200,518 | $2,468,000 | 0.05% |